| 2026-05-15 | 10-Q | 10.3 | First Amendment to the License Agreement between BioAtla, Inc. and Context Therapeutics Inc., dated as of May 14, 2026 |
|---|
| 2026-03-31 | 10-K | 10.37 | Retention Bonus Agreement between BioAtla, Inc. and Jay Short, effective March 20, 2026 |
|---|
| 2026-03-31 | 10-K | 10.36 | Form of Retention Bonus Agreement between BioAtla, Inc. and certain executive officers |
|---|
| 2026-03-31 | 10-K | 10.35 | Investment Agreement, dated as of December 30, 2025, by and among BioAtla, Inc., Inversagen AI, LLC and Alliance International Resources Corp. |
|---|
| 2025-11-21 | 8-K | 10.2 | Standby Equity Purchase Agreement, dated as of November 20, 2025, between BioAtla, Inc. and YA II PN, Ltd. |
|---|
| 2025-11-21 | 8-K | 10.1 | Form of Pre-Paid Advance Agreement. |
|---|
| 2025-08-07 | 10-Q | 10.1 | Lease Agreement between BioAtla, Inc. and HCP Torreyana, LLC, as amended. |
|---|
| 2024-12-20 | 8-K | 10.1 | Form of Securities Purchase Agreement, dated as of December 19, 2024 |
|---|
| 2024-09-23 | 8-K | 10.2 | Global Transaction Agreement between BioAtla, Inc. and Himalaya Therapeutics SEZC, dated as of September 23, 2024 |
|---|
| 2024-09-23 | 8-K | 10.1 | License Agreement between BioAtla, Inc. and Context Therapeutics Inc., dated as of September 23, 2024 |
|---|
| 2024-08-08 | 10-Q | 10.2 | Form of Non-Employee Director Restricted Stock Unit Agreement |
|---|
| 2024-08-08 | 10-Q | 10.1 | Amended and Restated Director Compensation Policy |
|---|
| 2024-05-14 | 10-Q | 10.2 | Form of Restricted Stock Unit Agreement |
|---|
| 2024-05-14 | 10-Q | 10.1 | China Clinical Trial Services Agreement, dated April 8, 2022, by and between BioAtla, Inc. and Himalaya Therapeutics Limited Company, as amended. |
|---|
| 2024-03-26 | 10-K | 10.25 | Form of Employee Stock Option Agreement |
|---|
| 2024-03-26 | 10-K | 10.24 | First Amendment to Master Clinical Trial Agreement between BioAtla, Inc. and Bristol-Myers Squibb Company |
|---|
| 2024-03-26 | 10-K | 10.17 | First Amendment to Lease with HCP Torreyana, dated January 16, 2019 |
|---|
| 2023-08-01 | 10-Q | 10.3 | Form of Stock Option Agreement (50%) |
|---|
| 2023-08-01 | 10-Q | 10.2 | Form of Stock Option Agreement (25%) |
|---|
| 2023-08-01 | 10-Q | 10.1 | Form of Stock Option Agreement |
|---|
| 2023-03-23 | 10-K | 10.31 | Amended and Restated BioAtla Director Compensation Policy |
|---|
| 2023-03-23 | 10-K | 10.24 | First Amendment to Master Clinical Trial Agreement between BioAtla, Inc. and Bristol-Myers Squibb |
|---|
| 2022-11-04 | 10-Q | 10.2 | Master Clinical Trial Collaboration Agreement, dated January 5, 2022, by and between BioAtla, Inc. and Bristol-Myers Squibb Company. |
|---|
| 2022-09-21 | 8-K | 10.1 | BioAtla, Inc. Management Change of Control Severance Plan |
|---|
| 2022-08-09 | 10-Q | 10.1 | China Clinical Trial Services Agreement, dated April 8, 2022, by and between BioAtla, Inc. and Himalaya Therapeutics Limited Company. |
|---|
| 2022-05-05 | 10-Q | 10.1 | BioAtla Director Compensation Policy |
|---|
| 2022-02-28 | 10-K | 10.31 | BioAtla Director Compensation Policy |
|---|
| 2022-02-28 | 10-K | 10.28 | Amendment No. 3 to Global Co-Development and Collaboration Agreement between BioAtla, Inc. and BeiGene, Ltd |
|---|
| 2022-02-28 | 10-K | 10.27 | Amendment No. 1 to Employee Share Purchase Plan |
|---|
| 2022-02-28 | 10-K | 10.26 | Amendment No. 2 to 2020 Equity Incentive Plan |
|---|
| 2022-02-28 | 10-K | 10.22 | Offer Letter between BioAtla, LLC and Christian Vasquez, dated October 22, 2015 |
|---|
| 2022-02-28 | 10-K | 10.21 | Offer Letter between BioAtla, LLC and Eric Sievers, dated June 17, 2019 |
|---|
| 2022-02-28 | 10-K | 10.20 | Severance Agreement between BioAtla, LLC and Richard Waldron, dated July 1, 2018 |
|---|
| 2022-02-28 | 10-K | 10.19 | Offer Letter between BioAtla, LLC and Richard Waldron, dated October 23, 2013 |
|---|
| 2021-11-15 | 10-Q | 10.2 | Form of Employee Stock Option Agreement |
|---|
| 2021-11-15 | 10-Q | 10.1 | Form of Non-Employee Director Stock Option Agreement |
|---|
| 2021-05-12 | 10-Q | 10.1 | Transition Agreement by and between BioAtla, Inc. and Carolyn Anderson Short, dated March 23, 2021. |
|---|